搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
2 天
on MSN
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
3 小时
Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
2 天
2seventy bio与百时美施贵宝停止多发性骨髓瘤疗法试验 预计节省8000万美元
据了解,2seventy bio和其合作伙伴百时美施贵宝宣布,将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究,旨在评估Abecma与来那度胺联合治疗,以及来那度胺单药治疗的效果。两家公司表示,这一决定是在对该研究的商业理由进行彻底审查后做出的。
FiercePharma
2 天
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
Zacks.com on MSN
1 天
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
阿思達克財經網
2 天
2seventy bio(TSVT.US)与百时美施贵宝(BMY.US)停止多发性骨髓瘤疗法试验 ...
据了解,2seventy ...
2 天
2seventy bio和百时美施贵宝暂停三期研究,预计节省成本
CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT)和百时美施贵宝公司(NYSE:BMY)联合宣布停止招募KarMMa-9三期研究。该研究旨在评估Abecma联合来那度胺维持治疗对自体干细胞移植后反应不佳的新诊断多发性骨髓瘤(NDMM)患者的疗效。 这一决定预计将在未来几年为2seventy bio节省超过8000万美元,并加速公司在2025年实现 ...
2 天
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
Pharmabiz
22 小时
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of ...
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Business Wire
2 天
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third ...
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
1 天
Leerink Partners上调2Seventy Bio股票目标价
Leerink Partners调整了对2Seventy Bio Inc. (NASDAQ: TSVT)的展望,将该股票的目标价从之前的15.00美元上调至25.00美元,同时维持"优于大市"评级。 此次调整是在KarMMa-9试验终止后做出的,该试验原本预计将成为自体BCMA CAR-T疗法Abecma收入增长的重要贡献者。 根据Leerink Partners的分析,尽管KarMMa-9试验终 ...
2 天
2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈